Special Issue "Extracellular Vesicles (EVs) in Formulation Development, Pre-clinical and Clinical Stages"
Deadline for manuscript submissions: closed (31 August 2022) | Viewed by 2422
Interests: cancer therapy; drug delivery; drug targeting; infectious disease; micelle; nanoparticles; nanotechnology; polymers; targeted therapies; HIV; antibody engineering; antibody–drug conjugates
Special Issues, Collections and Topics in MDPI journals
Special Issue in Scientia Pharmaceutica: Advances in Nanoparticle-Mediated Drug Delivery
Special Issue in International Journal of Molecular Sciences: Biomaterials and Their Composites for Biomedical Applications and Beyond
Special Issue in Pharmaceutics: Editorial Board Members’ Collection Series: Image-Guided and Targeted Theranostic Platforms
Extracellular vesicles (EVs) are a group of natural carriers that may have the capability delivered delivering active pharmaceutical ingredients (APIs) for better therapeutic results. EVs may help APIs bypass certain delivery barriers to improve drug concentration at the target site(s). Such strategies may also reduce systemic side effects and may allow for higher dosing for patients.
In this Special Issue, we are calling for manuscripts covering every possible step in a product cycle, starting from EV production and purification to final EV drug formulation as well as pre-clinical/clinical trials. We also encourage manuscripts to discuss potential regulatory affairs and quality assurance, as peer-reviewed articles are one critical source for regulatory agencies, such as the US FDA, to help their draft guidelines for the industry.
There are no restrictions as to which medical conditions can be discussed. Manuscripts must cover at least one of the following aspects to be eligible for this Special Issue:
- The production and purification of EVs without any APIs. The inclusion of in-process quality control and characterization tests as well as final tests is encouraged.
- Formulation processing development using EVs to deliver APIs. The inclusion of in-process testing to show the encapsulation/affiliation/conjugation of the APIs is encouraged as they are critical for future development.
- Formulation processing development using EVs to deliver APIs using cell line/animal models in pre-clinical stages to show significant improvements in drug delivery.
- Any clinical trials using EVs to deliver APIs at all stages.
- Regulatory affairs and quality assurance (RAQA) to discuss/help regulatory agencies provide guidance for the industry.
- Any other aspects that authors are interested in and willing to discuss in advance with the editorial team before drafting.
We are looking forward to receiving your manuscripts, and we appreciate your contributions.
Dr. Murali Mohan Yallapu
Dr. Hao Shi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- extracellular vesicles (EVs)
- formulation development processing
- clinical trials
- regulatory affairs and quality assurance (RAQA)